Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I–II Melanoma Patients at Risk of Disease Relapse
Authors:
- Evalyn E. A. P. MulderEMEvalyn E. A. P. Mulder
- Iva JohanssonIJIva Johansson
- Dirk J. GrünhagenDGDirk J. Grünhagen
- Dennie TempelDTDennie Tempel
- Barbara Rentroia-PachecoBRBarbara Rentroia-Pacheco
- Jvalini T. DwarkasingJDJvalini T. Dwarkasing
- Daniëlle VerverDVDaniëlle Verver
- Antien L. MooyaartAMAntien L. Mooyaart
- Astrid A. M. van der VeldtAstrid A. M. van der Veldt
- Marlies WakkeeMWMarlies Wakkee
- Tamar E. C. NijstenTNTamar E. C. Nijsten
- Cornelis VerhoefCornelis Verhoef
Open Access
Abstract
Background: The current standard of care for patients without sentinel node (SN) metastasis (i.e., stage I–II melanoma) is watchful waiting, while >40% of patients with stage IB–IIC will eventually present with disease recurrence or die as a result of melanoma. With the prospect of adjuvant therapeutic options for patients with a negative SN, we assessed the performance of a clinicopathologic and gene expression (CP-GEP) model, a model originally developed to predict SN metastasis, to identify patients with stage I–II melanoma at risk of disease relapse. Methods: This study included patients with cutaneous melanoma ≥18 years of age with a negative SN between October 2006 and December 2017 at the Sahlgrenska University Hospital (Sweden) and Erasmus MC Cancer Institute (The Netherlands). According to the CP-GEP model, which can be applied to the primary melanoma tissue, the patients were stratified into high or low risk of recurrence. The primary aim was to assess the 5-year recurrence-free survival (RFS) of low- and high-risk CP-GEP. A secondary aim was to compare the CP-GEP model with the EORTC nomogram, a model based on clinicopathological variables only. Results: In total, 535 patients (stage I–II) were included. CP-GEP stratification among these patients resulted in a 5-year RFS of 92.9% (95% confidence interval (CI): 86.4–96.4) in CP-GEP low-risk patients (n = 122) versus 80.7% (95%CI: 76.3–84.3) in CP-GEP high-risk patients (n = 413; hazard ratio 2.93 (95%CI: 1.41–6.09), p < 0.004). According to the EORTC nomogram, 25% of the patients were classified as having a ‘low risk’ of recurrence (96.8% 5-year RFS (95%CI 91.6–98.8), n = 130), 49% as ‘intermediate risk’ (88.4% 5-year RFS (95%CI 83.6–91.8), n = 261), and 26% as ‘high risk’ (61.1% 5-year RFS (95%CI 51.9–69.1), n = 137). Conclusion: In these two independent European cohorts, the CP-GEP model was able to stratify patients with stage I–II melanoma into two groups differentiated by RFS.Keywords
Funding Information
- Netherlands Enterprise Agency (IK18007)
This publication has 39 references indexed in Scilit:
- Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992-2013Journal of the American Academy of Dermatology, 2017
- Effects of time interval between primary melanoma excision and sentinel node biopsy on positivity rate and survivalEuropean Journal of Cancer, 2016
- Prognostic instrument for survival outcome in melanoma patients: based on data from the population-based Swedish Melanoma RegisterEuropean Journal of Cancer, 2016
- Tumor Cell Adhesion As a Risk Factor for Sentinel Lymph Node Metastasis in Primary Cutaneous MelanomaJournal of Clinical Oncology, 2015
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trialThe Lancet Oncology, 2015
- More People Die from Thin Melanomas (≤1 mm) than from Thick Melanomas (>4 mm) in Queensland, AustraliaJournal of Investigative Dermatology, 2015
- Development of a Prognostic Genetic Signature to Predict the Metastatic Risk Associated with Cutaneous MelanomaClinical Cancer Research, 2015
- The effect of delay time between primary melanoma biopsy and sentinel lymph node dissection on sentinel node status, recurrence, and survivalMelanoma Research, 2012
- Sentinel-Node Biopsy or Nodal Observation in MelanomaNew England Journal of Medicine, 2006
- High positive sentinel node identification rate by EORTC melanoma group protocolEuropean Journal of Cancer, 2006